Locations:

Tag: siRNA

Lp(a) particles floating among red blood cells

April 1, 2025/Heart, Vascular and Thoracic/Preventive Cardiology

Lepodisiran’s Large, Durable Lp(a) Reductions in Phase 2 Trial Boost Anticipation of Phase 3 Results

Small interfering RNA lowered lipoprotein(a) by 94% during six-month follow-up after a single dose

November 19, 2024/Heart, Vascular and Thoracic/Preventive Cardiology

Small-Interfering RNA Shows Cumulative Lp(a) Reduction With Successive Doses

Phase 2 trial of zerlasiran yields first demonstration of longer effect with each dose of an siRNA

November 13, 2023/Heart, Vascular and Thoracic/Preventive Cardiology

Novel siRNA Reduces Lipoprotein(a) by More Than 90% for 48 Weeks

Undetectable levels achieved for nearly nine months in phase 1 trial

April 4, 2022/Heart, Vascular and Thoracic/Preventive Cardiology

Novel siRNA Therapy Lowers Elevated Plasma Lipoprotein(a) in Phase 1 APOLLO Trial

Targeted mRNA blocking could be first effective approach specific to this cardiovascular risk factor

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

BackPage 1 of 1Next